Medicare drug makers face $1 million-a-day penalties

Drug makers that sign Medicare’s drug-price negotiation deals could soon be living under a much harsher penalty regime. In Washington, the Centers for Medicare & Medicaid Services, or CMS, is proposing to codify the Medicare Drug Price Negotiation Program and monitor compliance with agreement terms, with daily civil monetary penalties for violations.

The proposed rule also adds separate penalties for false information and for failure to pay rebates. That matters because it turns the program from a pricing framework into a compliance system with real financial consequences when a manufacturer misses the mark.

How the penalties break apart

CMS is not treating every problem the same way. A failure to follow the agreement terms would trigger a daily civil monetary penalty, while false information and unpaid rebates would be handled as separate offenses. The daily amount is set by statute at $1,000,000 and is updated each year under the Federal Civil Penalties Inflation Adjustments Improvements Act of 2015.

The proposal also reaches the Medicare Prescription Drug Benefit Program, better known as Part D. For companies that operate in that market, the message is straightforward: signing up for the program does not just bring a new price. It brings a set of rules that CMS says it will actively enforce.

Why the number matters

A million dollars a day is the kind of number that changes behavior even before anyone writes a check. It gives CMS a backstop if a manufacturer drags its feet, gives false information or skips a required rebate payment, and it raises the cost of treating the negotiation program like a paper exercise.

The agency’s proposal is aimed at making sure the negotiated-price system works as a governed program, not a loose understanding. For patients and Medicare administrators, the practical question is whether the people selling these drugs will now have a stronger reason to stay in line.